1. Biotransformation and mass balance of the SGLT2 inhibitor empagliflozin in healthy volunteers. (June 2015) Authors: Chen, Lin-Zhi; Jungnik, Arvid; Mao, Yanping; Philip, Elsy; Sharp, Dale; Unseld, Anna; Seman, Leo; Woerle, Hans-Jürgen; Macha, Sreeraj Journal: Xenobiotica Issue: Volume 45:Number 6(2015:Jun.) Page Start: 520 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Design of a 24-week trial of empagliflozin once daily in hypertensive black/African American patients with type 2 diabetes mellitus. (1st February 2018) Authors: Ferdinand, Keith C.; Seman, Leo; Salsali, Afshin Journal: Current medical research and opinion Issue: Volume 34:Number 2(2018) Page Start: 361 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose‐Dependent Glucosuria in Healthy Subjects. Issue 2 (27th March 2013) Authors: Seman, Leo; Macha, Sreeraj; Nehmiz, Gerhard; Simons, Gudrun; Ren, Bailuo; Pinnetti, Sabine; Woerle, Hans J.; Dugi, Klaus Journal: Clinical pharmacology in drug development Issue: Volume 2:Issue 2(2013:Apr.) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus. Issue 6 (25th June 2013) Authors: Kanada, Shigeto; Koiwai, Kazuki; Taniguchi, Atsushi; Sarashina, Akiko; Seman, Leo; Woerle, Hans J Journal: Journal of diabetes investigation Issue: Volume 4:Issue 6(2013:Dec.) Page Start: 613 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Population pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, in patients with type 2 diabetes. (13th August 2013) Authors: Riggs, Matthew M.; Staab, Alexander; Seman, Leo; MacGregor, Thomas R.; Bergsma, Timothy T.; Gastonguay, Marc R.; Macha, Sreeraj Journal: Journal of clinical pharmacology Issue: Volume 53:Number 10(2013:Oct.) Page Start: 1028 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Real‐world opportunity of empagliflozin to improve blood pressure control in African American patients with type 2 diabetes: A National Cardiovascular Data Registry "research‐to‐practice" project from the diabetes collaborative registry. Issue 2 (25th September 2018) Authors: Arnold, Suzanne V.; Seman, Leo; Tang, Fengming; Peri‐okonny, Poghni A.; Ferdinand, Keith C.; Mehta, Sanjeev N.; Goyal, Abhinav; Sperling, Laurence S.; Kosiborod, Mikhail Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 2(2019) Page Start: 393 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA‐REG OUTCOME trial. (28th June 2021) Authors: Pellicori, Pierpaolo; Fitchett, David; Kosiborod, Mikhail N.; Ofstad, Anne P.; Seman, Leo; Zinman, Bernard; Zwiener, Isabella; Wanner, Christoph; George, Jyothis; Inzucchi, Silvio E.; Testani, Jeffrey M.; Cleland, John G.F. Journal: European journal of heart failure Issue: Volume 23:Number 7(2021) Page Start: 1085 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Use of Intensive Glycemic Management in Older Adults with Diabetes Mellitus. Issue 6 (10th April 2018) Authors: Arnold, Suzanne V.; Lipska, Kasia J.; Wang, Jingyan; Seman, Leo; Mehta, Sanjeev N.; Kosiborod, Mikhail Journal: Journal of the American Geriatrics Society Issue: Volume 66:Issue 6(2018) Page Start: 1190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗